Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Eshetu, Teferi ^a,b   Abdo, Nasir ^c   Bedru, Kunuz H ^c   Fekadu, Sintayehu ^b   Wieser, Andreas ^d   Pritsch, Michael ^a,d   Löscher, Thomas ^a   Berens Riha, Nicole ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b JIMMA UNIVERSITY   (Ethiopia)

^c Jimma Zone Health Bureau   (Ethiopia)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

ACT; Artemether Lumefantrine; Ethiopia; Malaria; Plasmodium falciparum

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DIARRHEA; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG TOLERABILITY; ETHIOPIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MICROSCOPY; OUTCOME ASSESSMENT; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RECURRENT DISEASE; SCHOOL CHILD; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; ETHIOPIA; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866074608     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-240     Document Type: Article

References (49)

1. Federal Democratic Republic of Ethiopia, Ministry of Health, Malaria diagnosis and treatment guidelines for health workers in Ethiopia Ministry of Health, Addis Ababa 2 2004
2. World Health Organization, WHO Guidelines for the treatment of malaria WHO, Geneva 2006
3. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, Gathmann I, Mull R, Brockman A, White NJ, Nosten F, Trans R Soc Trop Med Hyg 2000 94 545 548 10.1016/S0035-9203(00)90082-8 11132386
4. Qinghaosu (artemisinin): the price of success. White NJ, Science 2008 320 330 334 10.1126/science.1155165 18420924
5. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Omari AA, Gamble C, Garner P, Cochrane Database Syst Rev 2005 4 D005564 16235412
6. Artemisinins: mechanisms of action and potential for resistance. Krishna S, Uhlemann AC, Haynes RK, Drug Resist Updat 2004 7 233 244 10.1016/j.drup.2004. 07.001 15533761
7. Qinghaosu in combinations. White NJ, Med Trop (Mars) 1998 58 Suppl 3 85 88
8. Spatial and temporal variations of malaria epidemic risk in Ethiopia: factors involved and implications. Abeku TA, van Oortmarssen GJ, Borsboom G, de Vlas SJ, Habbema JD, Acta Trop 2003 87 331 340 10.1016/S0001-706X(03)00123-2 12875926
9. Urban malaria and associated risk factors in Jimma town, south-west Ethiopia. Alemu A, Tsegaye W, Golassa L, Abebe G, Malar J 2011 10 173 10.1186/1475-2875-10-173 21699741
10. Ringwald P, Barrette A, Fairhurst R, Dondorp A, Kachur P, MacArthur J, Slutsker L, Plowe C, Dye C, Mendis K, Newman R, Olumese P, Sillah J, Warsame M, Global report on antimalarial drug efficacy and drug resistance: 2000-2010 World Health Organization, Geneva 2011
11. Evidence of artemisinin-resistant malaria in western Cambodia. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium, N Engl J Med 2008 359 2619 2620 10.1056/NEJMc0805011 19064625
12. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
13. Artemisinin-resistant malaria in Asia. Noedl H, Socheat D, Satimai W, N Engl J Med 2009 361 540 541 10.1056/NEJMc0900231 19641219
14. The threat of artemisinin-resistant malaria. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellems TE, Ringwald P, Newman RD, Plowe CV, N Engl J Med 2011 365 1073 1075 10.1056/NEJMp1108322 21992120
15. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. Anderson TJ, Nair S, Nkhoma S, Williams JT, Imwong M, Yi P, Socheat D, Das D, Chotivanich K, Day NP, White NJ, Dondorp AM, J Infect Dis 2010 201 1326 1330 10.1086/651562 20350192
16. The clinical efficacy of artemether/lumefantrine (Coartem). Makanga M, Krudsood S, Malar J 2009 8 Suppl 1 5 10.1186/1475-2875-8-S1-S5 19128455
17. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Barnes KI, Chanda P, Ab Barnabas G, Malar J 2009 8 Suppl 1 8 10.1186/1475-2875-8-S1-S8 19134197
18. World Health Organization, Global plan for artemisinin resistance containment (GPARC). Global Partnership to Roll Back Malaria & World Health Organization, Geneva 2011
19. Artemether-Lumefantrin (Coartem) and artesunate with sulfadoxine- pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia. Seboxa T, Mao P, Pinchouk N, Anbessie J, Alemu H, Diro E, Ethiop Med J 2010 48 285 291 21280430
20. Efficacy of six-dose regimen of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria, three years after its introduction into Ethiopia. Kefyalew T, Animut A, Tamene T, Jima D, Hailemariam A, Legesse M, Parasite 2009 16 129 134 19585891
21. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum Malaria in Northern Ethiopia. Kinfu G, Gebre-Selassie S, Fikrie N, Malar Res Treat 2012 2012 548710 22567536
22. Therapeutic efficacy of artemether/lumefantrine (Coartem(R)) against Plasmodium falciparum in Kersa, South West Ethiopia. Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengesha T, Parasit Vectors 2010 3 1 10.1186/1756-3305-3-1 20051120
23. In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia. Hwang J, Alemayehu BH, Hoos D, Melaku Z, Tekleyohannes SG, Teshi T, Birhanu SG, Demeke L, Gobena K, Kassa M, Jima D, Reithinger R, Nettey H, Green M, Malone JL, Kachur SP, Filler S, Malar J 2011 10 209 10.1186/1475-2875-10-209 21798054
24. Similar efficacy and safety of artemether-lumefantrine (Coartem) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Bassat Q, González R, Machevo S, Nahum A, Lyimo J, Maiga H, Mårtensson A, Bashraheil M, Ouma P, Ubben D, Walter V, Nwaiwu O, Kipkeu C, Lefèvre G, Ogutu B, Menéndez C, Malar J 2011 10 369 10.1186/1475-2875-10-369 22176931
25. Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, Swedberg G, Malar J 2012 11 58 10.1186/1475-2875-11-58 22369089
26. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. Four Artemisinin-Based Combinations (4ABC) Study Group, PLoS Med 2011 8 1001119 10.1371/journal.pmed.1001119 22087077
27. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, Frühauf H, Schaub B, Pfeil J, Peshu J, Hanpithakpong W, Rippert A, Juma E, Tsofa B, Mosobo M, Lowe B, Osier F, Fegan G, Lindegårdh N, Nzila A, Peshu N, Mackinnon M, Marsh K, PLoS One 2011 6 26005 10.1371/journal.pone.0026005 22102856
28. World Health Organization, Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciaprum malaria WHO/HTM/RBM, Geneva 2003
29. In vivo parasitological measures of artemisinin susceptibility. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, DAlessandro U, Day NP, de Vries PJ, Dorsey G, Guthmann JP, Mayxay M, Newton PN, Olliaro P, Osorio L, Price RN, Rowland M, Smithuis F, Taylor WR, Nosten F, White NJ, J Infect Dis 2010 201 570 579 10.1086/650301 20085495
30. Determination of genetic variation within Plasmodium falciparum by using enzymatically amplified DNA from filter paper disks impregnated with whole blood. Kain KC, Lanar DE, J Clin Microbiol 1991 29 1171 1174 1864936
31. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Snounou G, Beck HP, Parasitol Today 1998 14 462 467 10.1016/S0169-4758(98)01340-4 17040849
32. Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: adjustment of parasitological outcomes and assessment of genotyping effectiveness. Mugittu K, Adjuik M, Snounou G, Ntoumi F, Taylor W, Mshinda H, Olliaro P, Beck HP, Trop Med Int Health 2006 11 1350 1359 10.1111/j.1365-3156.2006.01688.x 16930256
33. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN, Mol Biochem Parasitol 1993 61 315 320 10.1016/0166-6851(93)90077-B 8264734
34. Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. Schneider P, Schoone G, Schallig H, Verhage D, Telgt D, Eling W, Sauerwein R, Mol Biochem Parasitol 2004 137 35 41 10.1016/j.molbiopara.2004.03.018 15279949
35. Stability of gametocyte-specific Pfs25-mRNA in dried blood spots on filter paper subjected to different storage conditions. Pritsch M, Wieser A, Soederstroem V, Poluda D, Eshetu T, Hoelscher M, Schubert S, Shock J, Loescher T, Berens-Riha N, Mal J. 2012 11 138 10.1186/1475-2875-11-138
36. Rapid and simple method for purification of nucleic acids. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J, J Clin Microbiol 1990 28 495 503 1691208
37. Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Gürkov R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, Krause E, Schmidt M, Hempel JM, Löscher T, Malar J 2008 7 179 10.1186/1475-2875-7-179 18796142
38. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. White NJ, van Vugt M, Ezzet F, Clin Pharmacokinet 1999 37 105 125 10.2165/00003088-199937020-00002 10496300
39. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Kokwaro G, Mwai L, Nzila A, Expert Opin Pharmacother 2007 8 75 94 10.1517/14656566.8.1.75 17163809
40. Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations. Travassos MA, Laufer MK, Pediatr Res 2009 65 64R 70R 10.1203/PDR.0b013e3181a0977e 19918214
41. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of dormancy, a partial cytostatic effect of the drug, and its implication for treatment regimens. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H, Parasitology 2000 121 237 246 10.1017/S0031182099006332 11085244
42. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Witkowski B, Lelièvre J, Barragán MJ, Laurent V, Su XZ, Berry A, Benoit-Vical F, Antimicrob Agents Chemother 2010 54 1872 1877 10.1128/AAC.01636-09 20160056
43. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Bousema T, Drakeley C, Clin Microbiol Rev 2011 24 377 410 10.1128/CMR.00051-10 21482730
44. Submicroscopic Plasmodium falciparum gametocyte carriage is common in an area of low and seasonal transmission in Tanzania. Shekalaghe SA, Bousema JT, Kunei KK, Lushino P, Masokoto A, Wolters LR, Mwakalinga S, Mosha FW, Sauerwein RW, Drakeley CJ, Trop Med Int Health 2007 12 547 553 10.1111/j.1365-3156.2007. 01821.x 17445146
45. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein RW, J Infect Dis 2006 193 1151 1159 10.1086/503051 16544256
46. Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations. Lawpoolsri S, Klein E, Singhasivanon P, Yimsamran S, Thanyavanich N, Maneeboonyang W, Hungerford L, Maguire J, Smith D, Malar J 2009 8 159 10.1186/1475-2875-8-159 19604346
47. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P, AmJTrop Med Hyg 2011 84 137 140
48. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S, Wilairatana P, Kano S, Ringwald P, Looareesuwan S, Korean J Parasitol 2007 45 111 114 10.3347/kjp.2007.45.2.111 17570973
49. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, Lancet 2007 369 757 765 10.1016/S0140-6736(07)60160-3 17336652